ES, electrospray; MS. mass spectrometry; UV, ultraviolet; AUC, area under the concentration-time curve; QC, quality control; DEV. deviation from expected; and AU, absorbance units.
olized by cytochrome P-450 3A enzymes in liver and intestine [3] ,' Quantification of SRL in biological matrices is a challenge because the high potency of this agent requires assays that can quantify low concentrations of drug. Moreover, if the assay is to be of practical utility, the technique must rely on equipment that is generally available in clinical laboratories.
Use of liquid chromatographyelectrospray-mass spectrometry (LC-ES-MS) equipment achieves a sensitivity of -0.25 ng from 1 mL of whole blood [4, 5] . More appropriate methods involve HPLC with ultraviolet detecting equipment (HPLC-UV) that is cornmonly available [6] [7] [8] [9] [10] . HPLC-UV methods described by Yatscoff et a!. [6] with modifications by Fryer et a!. [7] have been used to analyze whole blood from rabbit recipients of heterotopic heart transplants; by Wang et al. [9] for rat serum, plasma, and whole blood, as well as monkey serum; and by Napoli and Although the amount of analyte in the specimen is the major factor limiting the quantification of SRL, additional limitations include the recovery of analyte during sample processing, the volume of specimen that can be analyzed without substantial interference, and the volume of specimen available. Whole blood is chosen as the sample matrix because 95% of SRL is distributed into cellular elements [11] , and current technologies are not amenable for routine quantification of the low concentrations (ngfL) found in plasma. The present method achieves a sensitivity of 1 ng from 1 mL of whole blood.
The results presented herein document SRL trough concentrations between <1 and 77 j.tg/L for subjects who received daily SRL doses between 1 and 52 mg (0.5-7.0 mg/m2) in combination with CsA doses that were selected to maintain a 24-h average CsA concentration within the range of 2 50-550 tg/L [12] .
We have used a modified version of our original HPLC-UV method [8] during the past 21 months to determine SRL concentrations in 1866 blood specimens from all 57 subjects recruited into phase 111! clinical trials. The studies were concentration controlled for CsA but not for SRL. Our standardized protocol for obtaining blood samples included serial trough concentrations and several 24-h pharmacokinetic studies performed at regular intervals, and was approved by our insti- Third, SRL concentrations for quality control (QC) were changed to 4, 12, and 32 gfL; one set was injected immediately after the calibration curve (set A), and the other set after the unknowns (set B) at the end of the analytical run. Fourth, adjustments were made in the proportions of methanol and water in the mobile phase (between 84:16 and 86:14) when new chromatographic columns were installed, to provide the best resolution among SRL, internal standard, and endogenous whole-blood substances peaks. The final modification, an increase in mobile-phase flow rate, was the result of an evaluation of flow rates from 0.5 to 1.0 mL/min. In effect, either 0.5 or 0.7 inL/min was used for the analyses presented herein.
Among 68 consecutive analytical runs performed during the past 9 months, 15 included nine-point (blank, 1, and 2-50 igfL concentrations) calibration curves and 47 included eight-point (blank and 2-50 ig/L concentrations) calibration curves, and all of these 62 runs included QC sets A and B (two each of the 4, 12, and 32 .tg/L) and up to 53 samples from human subjects. The remaining six analytical runs included only QC set A (one sample at each of the three concentrations) and <10 samples from human subjects, for which the calibration curve of the previous day was used to calculate the SRL concentrations of the latter runs. The order of injection into the HPLC apparatus was as follows: calibration curve samples, QC set A, human samples, QC set B.
STAT! STICAL

EVALUATION
Using calibration and QC material data from 15 analytical runs, we evaluated two ratios, SRL peak height to internal standard peak height and SRL peak area to internal standard peak area. The weighted least-squares linear regression function of SPSS-SV statistical software (SPSS, Chicago, IL), with a weighting factor of 1/expected concentration, was used to estimate the slopes and intercepts. The CV and deviation from the expected concentrations (DEV) were determined from the calculated SRL concentrations of the calibration and QC materials to assess if either ratio provided a higher degree of accuracy.
The peak height ratio method was used to calculate the SRL concentrations in human specimens from 68 analytical runs. If the calculated SRL concentration in a calibration sample differed by >15% or 8% from the expected concentrations at <20 .tg/L and >20 .tg/L, respectively, the measurement was omitted from the calculations of slope and intercept. Intraday precision was monitored by duplicate measurements at the three QC concentrations.
The interday precision was based on CV and DEV from the means of the calibration and QC materials. During the present evaluation period, the chromatographic columns were changed twice, new dilutions of methanolic SRL solutions used for supplementing calibration materials were prepared three times, new dilutions of internal standard were prepared five times, and three lots of QC material were used.
SRL Results Because the precision of the peak area ratio method used previously [8] was limited by the presence of peaks eluting at retention times close to those of SRL and the internal standard and by the width of the analyte and internal standard peaks, a procedural change to use of the peak height ratio was evaluated. Fig. 1 provides a representative example of the chromatographic resolution at 2 ig/L SRL with comparison with a sample of SRL-free whole blood. No difference between the two methods was discerned according to interday means, CV, or DEV, when the area and height ratios of the SRL to internal standard peak in whole-blood samples supplemented at eight SRL concentrations (1-50 g/L) from 15 separate and consecutive analyses were compared.
Of the 135 samples compared, coeluting peaks in nine of the chromatographic traces, subsequently traced to contamination of disposable pipette tips through contact with latex gloves, precluded quantification of SRL peak area and height. Additional confirmation of the peak height method was Samples analyzed after calibration curve and before unknowns. "Samples analyzed after unknowns at end of analytical run. AU, measurement to 1 ng satisfies the definition for the limit of quantification (i.e., 10-fold baseline noise) and our own criteria for limit of sensitivity (i.e., interday CV slS%).
ValId n#{176}
The stability of SRL extracts for up to 24 h was verified by comparing the concentrations of SRL in QC materials injected immediately after the calibration curve (set A) with those injected at the end of the analytical run (set B). The DEV values ranged from -1% to -9% and were not different between sets
A and B ( Table 1) . In an effort to increase sample throughput, we investigated the impact of increased flow rates. Peak-to-peak resolution did not change significantly with 0.5-0.8 mL/min flow rates; however, the peak-to-peak resolution was compromised at flow rates >0.8 mL/min. A 30% reduction in SRL peak area, observed at a flow rate of 0.7 mL/min, produced no highly significant impact on the SRL concentrations in the QC materials compared with those analyses of a flow rate of 0.5 mL/min. Only the set A mean SRL concentrations at 32 g/L, but not at 4 or 12 g/L, were marginally different (30.4 ± 3.1 vs 28.9 ± 2.4; P = 0.044). In contrast, the mean values of the corresponding set B showed no difference (29.3 ± 1.8 vs 29.0 ± 2.0; P = not significant). Therefore, the increased 0.7 mL/min flow rate used for the latter 21 of the 68 assays did not diminish assay performance, although it reduced the chromatographic time by 11 mm per sample.
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Concern with regard to the interday precision at low SRL concentrations (<5 i.tg/L) in human samples prompted us to reanalyze specimens with SRL concentrations was detected by calculating the mean DEV between the observed and expected SRL concentrations in the QC materials. Minor errors in the preparation of the methanolic SRL stock solutions or analytical losses of SRL from previously frozen QC materials as compared with freshly prepared calibration materials may explain these observations. The present data are superior to the report of a ± 13% analytical bias by Wang et al. [9/ .
The long-term stability of method accuracy and precision was proven in spite of the fact that the linear range was narrowed from 2-100 g/L to 1-50 .tg/L, the mobile phase composition was adjusted periodically, the flow rate was increased, and new lots of QC material, methanolic SRL, and internal standard solutions were prepared frequently. The stability of sample extracts for up to 24 h in the autosampler allowed analysis of >50 samples per day. Few samples required reanalysis.
In addition to the previous suggestions for maintaining the technical performance of this method [8] , we also recommend monitoring the UV lamp energy and changing the lamp often. With our detector, the internal standard peak height is -0.003 AU, and the peak height of 10 ng of SRL is 0.00l AU; thus, a high level of lamp energy and a low level of baseline noise (baseline noise increases with lamp age) are critical for maintenance of analyte sensitivity. Moreover, the whole blood used for preparation of calibration and QC materials must be freshly collected from healthy volunteers into EDTA-containing collection tubes. Although interference due to personal medications has not been found, it is prudent to analyze the individual blood samples for interfering substances before pooling. Such a blood pool can he used for up to 2 months if stored at 4 #{176}C.
Finally, we have found that the HPLC column lifetime is -3 months. Column age primarily affects peak symmetry, but not peak-to-peak resolution, and can be monitored by daily visual inspection of the shape of the internal standard peak and through peak broadening, which presents as decreasing SRL concentrations in the QC material.
This present method has afforded insight into clinical management of patients under SRL treatment.
Statistical analysis of data from 115 24-h pharmacokinetic studies reveals a robust relation between overall drug exposure and the 24-h SRL trough concentration.
Studies in which this analytical method is being used for development of pharmacokinetic/pharmacodynamic models that explain SRL effects in humans are currently underway.
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